 LEXINGTON, Mass., Sept. 16, 2021 GLOBE NEWSWIRE -- Agenus NASDAQ: AGEN, an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented final results from the BalZal combination study at the European Society for Medical Oncology ESMO Virtual Conference 2021 in an abstract titled Balstilimab anti-PD-1 in combination with zalifrelimab anti-CTLA-4: final results from a Phase 2 study in patients pts with recurrentmetastatic RM cervical cancer CC. 